Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 73Colonic Neoplasms 14Rectal Neoplasms 13Neoplasm Metastasis 12Stomach Neoplasms 8Pancreatic Neoplasms 5Advanced Solid Tumors 5Neoplasms 4Colorectal Cancer Metastatic 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma 3Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Colorectal Cancer 2Adenocarcinoma Of Esophagus 2mCRC 1Urologic Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Solid Tumor 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24Oxaliplatin 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 18Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × trifluridine tipiracil drug combination × Clear all
NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡